Process / pipelineClinical / epidemiology

Bayesian Phase II Clinical Trial — Early Efficacy Evaluation with Bayesian Inference

A Bayesian Phase II clinical trial applies Bayesian statistical inference to the standard Phase II objective of evaluating whether an experimental treatment shows sufficient early-phase efficacy to justify progression to a Phase III trial. By combining prior information with accumulating trial data, it enables principled interim monitoring, flexible stopping rules, and updated probability statements about treatment effect — all without the multiple-testing penalties that burden frequentist sequential designs.

Open in MethodMindSoonVideoSoon

Read the full method

Members only

Sign in with a free account to read this section.

Sign in

Sources

  1. Thall, P. F., & Simon, R. (1994). Practical Bayesian guidelines for phase IIB clinical trials. Biometrics, 50(2), 337–349. DOI: 10.2307/2533377
  2. Berry, D. A. (2006). Bayesian clinical trials. Nature Reviews Drug Discovery, 5(1), 27–36. DOI: 10.1038/nrd1927

Related methods

ScholarGateBayesian Phase II Clinical Trial (Bayesian Phase II Clinical Trial Design). Retrieved 2026-06-04 from https://scholargate.app/en/epidemiology/bayesian-phase-ii-clinical-trial